Please login to the form below
Hodgkin lymphoma
This page shows the latest Hodgkin lymphoma news and features for those working in and with pharma, biotech and healthcare.
bluebird bio to separate oncology and rare diseases units
It will also retain research and development responsibilities for bluebird’s oncology pipeline of cellular therapies, which are focused on non-Hodgkin’s lymphoma, acute myeloid leukaemia, next-generation multiple myeloma
Latest news
-
FDA sets January decision date for Xalkori in ALK-positive lymphoma
ALCL is a rare form of non-Hodgkin lymphoma, and is characterised either as ALK-positive or ALK-negative disease. ... ALK-positive ALCL is the most common type and is a fast-growing lymphoma that causes T-cell mutations.
-
Keytruda doubles five-year survival rate in NSCLC
Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer,
-
Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC
Tyvyt has also been approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma (cHL).
-
World Castleman Disease Day
The disorder is just as serious and life-threatening as many rare blood cancers, including progressive non-Hodgkin’s lymphoma.
-
Keytruda hits primary endpoint in confirmatory lymphoma trial
Interim analysis demonstrates improvement in progression-free survival. Merck &Co/MSD’s Keytruda has hit the primary endpoint in a confirmatory phase 3 trial in classical Hodgkin lymphoma (cHL), three years ... Patients with classical Hodgkin lymphoma
More from news
Approximately 6 fully matching, plus 207 partially matching documents found.
Latest Intelligence
-
Growing evidence supports the important role of biosimilars in healthcare
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
-
Chinese biotech’s global ambitions
CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which
-
Deal Watch November 2016
relapsed or refractory aggressive CD19+ Non-Hodgkin Lymphoma.
-
Deal Watch June 2016
on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Charles Morris appointed chief development officer at ImmunoGen
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Australian Flu and the dilemma of naming diseases
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
-
Oncology drugs under AMNOG
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Sinovac’s COVID-19 vaccine appears safe in older adults
- bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- Bedrock’s strong start to 2021
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- Enabling Patient-Focused Research Through Virtual Clinical Trials
- Innovative Approaches to Managing Mental Health Conditions
- Newcells Biotech secures over £5m for 3D tissue models
- FDA briefing document backs J&J’s one-dose COVID-19 vaccine
PMHub
Attigo (part of the Mednet Group)
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
